Exploring the Potential of Riluzole in Stimulating Brain-Derived Neurotrophic Factor Release from Human Platelets: Implications for Depression Treatment

Abstract

This study explores the potential of riluzole, a drug used in depression treatment, to stimulate the release of brain-derived neurotrophic factor (BDNF) from healthy human platelets. BDNF plays crucial roles in neuronal survival, activity modulation, and neurotransmitter regulation within the central nervous system. While the source and peripheral function of BDNF remain unclear, its presence in serum has been established. Pharmacological interventions have shown that circulating BDNF, stored in platelets, can be released through treatment. However, the origin of this protein within platelets remains unknown. Notably, reduced serum levels of BDNF have been implicated in the pathophysiology of depression, underscoring its relevance in mood disorders. Riluzole, known for its ability to lower extracellular glutamate levels and increase BDNF expression, has emerged as a potential antidepressant agent. The investigation aims to elucidate whether riluzole treatment can directly stimulate the release of BDNF from human platelets at therapeutic concentrations. Such findings could enhance our understanding of riluzole's mechanism of action in depression treatment, shedding light on its role in modulating BDNF levels.